

Adult CIRB - Late Phase Emphasis Meeting Agenda

March 19, 2026

I Continuing Review

A071702, A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma (Version Date 08/04/25)

II Continuing Review

A151804, Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events (Version Date 06/03/24)

III Continuing Review

NRG-GU008, Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE*) (Version Date 08/13/24)

IV Continuing Review

NRG-GU010, Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (Version Date 11/14/25)

V Continuing Review

NRG-HN009, Protocol NRG-HN009, Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m² Every Three Weeks versus Radiation with Weekly Cisplatin at 40 mg/m² for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (NCT05050162) (Version Date 10/25/22)



VI Continuing Review

S1803, Phase III Study of Daratumumab and Hyaluronidase-FIHJ (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) (Version Date 01/16/26)

VII Continuing Review

S2001, Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations (Version Date 10/27/25)

VIII Continuing Review

S2007, A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases (Version Date 01/06/25)
